MedTrace Logo

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

NCT02821013 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 614

Last updated 2026-05-12

No results posted yet for this study

Summary

The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.

Conditions

  • Unresectable/Metastatic Melanoma

Interventions

DRUG

Intermittent PD-1 inhibitor therapy

DRUG

Continuous PD-1 inhibitor therapy

Sponsors & Collaborators

  • Melanoma and Skin Cancer Trials Limited

    collaborator OTHER

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Xinni Song · Ottawa Hospital Research Institute

  • Tara Baetz · Cancer Centre of Southeastern Ontario at Kingston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2027-12-31
Completion
2029-12-31

Countries

  • Australia
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02821013 on ClinicalTrials.gov